Clinical Trial Detail

NCT ID NCT02079636
Title A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

lung non-small cell carcinoma

Therapies

LY3023414

Abemaciclib

Gemcitabine

Pemetrexed Disodium

Ramucirumab

Age Groups: adult

No variant requirements are available.